ZA200801402B - Use of 2-phenyl-L, 2-ethanediol-(DI) carbamates for treating epileptogenesis and epilepsy - Google Patents

Use of 2-phenyl-L, 2-ethanediol-(DI) carbamates for treating epileptogenesis and epilepsy

Info

Publication number
ZA200801402B
ZA200801402B ZA200801402A ZA200801402A ZA200801402B ZA 200801402 B ZA200801402 B ZA 200801402B ZA 200801402 A ZA200801402 A ZA 200801402A ZA 200801402 A ZA200801402 A ZA 200801402A ZA 200801402 B ZA200801402 B ZA 200801402B
Authority
ZA
South Africa
Prior art keywords
ethanediol
carbamates
epilepsy
phenyl
treating epileptogenesis
Prior art date
Application number
ZA200801402A
Other languages
English (en)
Inventor
Roy E Twyman
Zhao Boyu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37637731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200801402(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA200801402B publication Critical patent/ZA200801402B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA200801402A 2005-07-12 2008-02-11 Use of 2-phenyl-L, 2-ethanediol-(DI) carbamates for treating epileptogenesis and epilepsy ZA200801402B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69862505P 2005-07-12 2005-07-12

Publications (1)

Publication Number Publication Date
ZA200801402B true ZA200801402B (en) 2009-10-28

Family

ID=37637731

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200801402A ZA200801402B (en) 2005-07-12 2008-02-11 Use of 2-phenyl-L, 2-ethanediol-(DI) carbamates for treating epileptogenesis and epilepsy

Country Status (16)

Country Link
US (1) US20070021501A1 (fr)
EP (1) EP1906946A2 (fr)
JP (1) JP2009501223A (fr)
KR (1) KR20080028485A (fr)
CN (1) CN101309680A (fr)
AR (1) AR054550A1 (fr)
AU (1) AU2006269462A1 (fr)
BR (1) BRPI0613010A2 (fr)
CA (1) CA2615127A1 (fr)
EA (1) EA200800295A1 (fr)
EC (1) ECSP088172A (fr)
IL (1) IL188728A0 (fr)
NO (1) NO20080739L (fr)
TW (1) TW200744575A (fr)
WO (1) WO2007008551A2 (fr)
ZA (1) ZA200801402B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6005357B2 (ja) * 2008-05-16 2016-10-12 ノノ インコーポレイテッド てんかんの治療
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
JP6062077B2 (ja) * 2013-03-12 2017-01-18 バイオ−ファーム ソリューションズ カンパニー リミテッド 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｐｅｄｉａｔｒｉｃｅｐｉｌｅｓｙａｎｄｅｐｉｌｅｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅｓ｝
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
AU2016312526B2 (en) * 2015-08-24 2021-09-09 Zogenix International Limited Methods of treating lennox-gastaut syndrome using fenfluramine
JP6807941B2 (ja) * 2016-02-29 2021-01-06 バイオ−ファーム ソリューションズ カンパニー リミテッド スルファメート誘導体化合物、その製造方法および用途
US20190022166A1 (en) * 2017-07-18 2019-01-24 Creative Bio-Peptides Inc. Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders
CN109920550A (zh) * 2018-12-25 2019-06-21 天津大学 一种基于dMRI研究青少年肌阵挛性癫痫的方法
CN115501344A (zh) * 2022-09-29 2022-12-23 重庆医科大学 一种铁螯合剂的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
AU3304997A (en) * 1996-05-31 1998-01-05 Southern Illinois University Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation
DE60003791T2 (de) * 1999-02-09 2004-02-05 The University Of Virginia Alumni Patents Foundation Felbamat-derivate
US6562867B2 (en) * 2001-02-27 2003-05-13 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
NZ527989A (en) * 2001-02-27 2005-12-23 Ortho Mcneil Pharm Inc Use of a halogenated 2-phenyl-1,2-ethanediol dicarbamate enantiomer or enantiomeric mixture wherein one enantiomer predominates for preventing or treating bipolar disorder

Also Published As

Publication number Publication date
AU2006269462A1 (en) 2007-01-18
NO20080739L (no) 2008-04-10
ECSP088172A (es) 2008-03-26
EA200800295A1 (ru) 2008-12-30
IL188728A0 (en) 2008-11-03
KR20080028485A (ko) 2008-03-31
WO2007008551A3 (fr) 2008-06-19
WO2007008551A2 (fr) 2007-01-18
CN101309680A (zh) 2008-11-19
TW200744575A (en) 2007-12-16
BRPI0613010A2 (pt) 2010-12-14
US20070021501A1 (en) 2007-01-25
AR054550A1 (es) 2007-06-27
EP1906946A2 (fr) 2008-04-09
JP2009501223A (ja) 2009-01-15
CA2615127A1 (fr) 2007-01-18

Similar Documents

Publication Publication Date Title
ZA200801402B (en) Use of 2-phenyl-L, 2-ethanediol-(DI) carbamates for treating epileptogenesis and epilepsy
EP1968583A4 (fr) Composes, essais et methodes de traitement
TWI367780B (en) Catalytic plant and process
IL217882A0 (en) Polyurethanes, polyurethane(ureas) sulfur-containing polyurethanes and sulfer-containing polyurethane(ureas and methods of preparation
EP1795634A4 (fr) Fil de cuir et procede d'elaboration correspondant
EP1883709A4 (fr) Micro-arn humains et procedes d'inhibition de ceux-ci
IL228770A0 (en) processes and intermediates
ZA200705951B (en) Hydroprocessing catalyst, preparation method thereof and use of same
EP1945284A4 (fr) Dispositifs de type seringue, leurs elements constitutifs et procedes de formation d'un agent medicamenteux dans lesdits dispositifs
EP1843835A4 (fr) Reacteur a buse et procede d'utilisation
GB0511749D0 (en) Resisting the spread of unwanted code and data
EP1931344A4 (fr) Dispositifs de traitement des vaisseaux
ZA200701488B (en) Plant treatment material
GB0515090D0 (en) Novel epilepsy treatment
IL189165A0 (en) Novel formulations comprising fenofibrate and a statin, and related methods of treatment
EP1888056A4 (fr) Utilisation du ladostigil pour traiter la sclerose en plaques
EP1817039A4 (fr) Traitement et prevention de l'epilepsie
ZA200709024B (en) Method of well treatment and construction
GB0500451D0 (en) Hair treatment apparatus
EP1606418A4 (fr) Methodes de diagnostic et de traitement de l'epilepsie
GB0402629D0 (en) Reactor and process
SG126059A1 (en) Tunable mask apparatus and process
SI1809273T1 (sl) Uporaba 2-fenil-1,2-etandiol-(di)karbamatov za zdravljenje epileptogeneze
ZA200704725B (en) Product and method of treatment
ZA200702195B (en) Use of 2-phenyl-1,2-ethanediol (Dl) carbamates for treating epileptogenesis and epilepsy